This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The IPO market may not be at the go-go levels of the late 1990s, but the environment is still fairly bullish. This is especially the case with technology companies and biotechs. Note that there have been ten deals that have posted returns of over 100%.
HD DB C MS.PRE DTK MS.PRF MS.PRG MS.PRA CS BAC GS TWLO MS.PRI T JPM MS.PRK MS
Bank of America (BAC) just reported an excellent second quarter. Additionally, it recently announced an approved capital return program for shareholders that is quite attractive. As a long-term Bank of America shareholder, I believe continuing to hold shares at these levels makes sense. Strong fundamentals and a continued economic expansion should provide positive share price appreciation.
BAC BRK.A BAC
Financial stocks jumped on Monday although the broader market struggled, as impressive economic data and quarterly results failed to boost investors’ confidence. Moreover, energy stocks weighed on markets. The Dow made meager gains, while the S&P 500 and Nasdaq ended lower. Investors also keenly watched President Donald Trump and Russian president Vladimir Putin’s summit in Helsinki, Finland. However, reaction to a joint conference by the two was muted.
CAT XOM GS.PRB GS.PRA BAC GS GLSSP TDW GLFMQ JBK GLF BAC GSC GS.PRICL TFG GSJ GS.PRJ GS.PRI JNJ GS.PRD CVX GS.PRC TDW.WSA TDW.WSB GJS GS.PRN GS.PRK
Traders and investors will want to keep their eyes on three key factors in the week ahead. And looking beyond the week, as these factors evolve, so should equities. Trade policy developments will continue to weigh heavily for the stock market, and volatility will remain elevated until trade tensions are resolved or until the market grows numb to them, assuming they do not take a turn for the far worse.
BAC BAC AMZN URI NFLX XRT
424B2 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-224523 The information in this preliminary prospectus supplement is not complete and may be changed. We may not sell the depositary shares until we deliver a final prospectus supplement. This preliminary
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, July 16.
WFCNP FB DB WFC.PRL NFLX WFC.PRJ ENB BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO SPOT WFC.PRN TWTR WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS BAC C UNP SE ENB JPM SBUX TRN
The market didn’t start the new trading week nearly as bullishly as it ended the previous one. When all was said and done, the S&P 500 ended the day a tad in the red, led lower by no stock in particular. The most noteworthy losers were Ford Motor (NYSE:F) and Chesapeake Energy (NYSE:CHK), which are noteworthy names, but not exactly heavy hitters.
SEE CKRGZ F CHKVP AMD NYTAB CHKDH CHKVZ CHKDG CHKWZ BAC EMN.WS CHKDJ CHKDP CHK EMN CHK.WI CHK.PRD DIS
On Saturday afternoon I was watching Regis “Rougarou” Prograis fight on ESPN. If you’re a boxing fan, you’ve got to take a look at this heavy fisted southpaw. He’s got the entire city of New Orleans behind him and he brings a ton of energy to the ring. The kid is tenacious and I think he has the mark of a true champion.
IBM BAC GEC GE C GILD CMCSA TWX NFLX CA TWC BAC JNJ AVGO GNE
Earnings season is now in full session after JP Morgan (JPM - Free Report) and Citigroup (C - Free Report) beat earnings on Friday while Wells Fargo (WFC - Free Report) stumbled. Bank of America (BAC - Free Report) and Blackstone (BLK - Free Report) were the headliners on Monday, both surpassing expectations and boosting investor confidence.
WFCNP MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA BAC WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN MS WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS BAC C MS.PRI MS.PRK
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to BAC / Bank of America Corp. on message board site Silicon Investor.
as of ET